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Abstract
Chronic diseases strongly affect individuals’ health status. In aggregate terms, this impact 
is reflected by the stock of health, which measures the amount of health of a population 
in a given period of time.
Objectives: To measure of the relative burden of chronic illness by assessing health-
related quality of life (HRQoL) using the EQ-5D-5L instrument. To rank diseases 
according to their associations with the stock of health. To calculate the stock of health 
of the Spanish population and the amount of health loss attributable to each chronic 
disease from a social perspective. 
Data and Methods: Data were gathered from the Spanish Health Survey (ENSE 2011-
12, N = 20,587). Models: A population weighted least squares model was used.
Results: Chronic diseases represent 19.19% of the stock of health losses in Spain 
compared to a country free from those diseases. In Spain, the stock of health in 2011 was 
31.86 million units on the VAS.
The diseases with the strongest impact in terms of loss of stock of health at the individual 
level were mental illness and embolism, stroke or cerebral hemorrhage. Collectively, the 
diseases with the largest impact included osteoarthritis, arthritis, or rheumatism, chronic 
back pain, and high blood pressure.
Keywords: Stock of health, Chronic diseases, Visual Analog Scale, EQ-5D, EQ-5D-5L


































































A stock variable measures magnitude at an instant in time. Health is “the state of 
complete physical, mental and social well-being and not merely the absence of disease or 
infirmity” (WHO, 1946). This definition emphasizes the multidimensional and subjective 
features of health. Health care outcomes should therefore be measured 
multidimensionality and include the subjective experience of the patient (Saarni et al., 
2006). In this paper, we described the stock of health concept as defined by Grossman 
(Grossman, 1972). The stock of health is the amount of health of a population in a 
geographical area. The stock of health variable considered in our analyses is the amount 
of health of a population of a country. Like Grossman’s model, this assessment assumes 
that individuals inherit an initial stock of health that depreciates over time at an increasing 
rate after some stage in the life cycle. Stock of health can be increased by health 
investments. In this paper, we quantify the stock of health of the population in a country 
as a macroeconomic variable akin to how the gross domestic product (GDP) or consumer 
price index measures wealth or price evolution for a specific population.
Health-related quality of life (HRQoL) combined with quantity of life provide a holistic 
snapshot of health. There are many HRQoL instruments, but there is still no gold standard 
in HRQoL measurement. The EQ-5D is one of the most used instruments worldwide. The 
EQ-5D is a multiattribute, generic, preference-based health status measure, applicable to 
general populations and patients with various diseases (Brooks, 1996). Despite its brevity, 
the EQ-5D has consistently shown excellent psychometric properties (Stucki et al., 1995; 
Fisk, Brown & Sketris, 2005; Lamers et al., 2006; Van Stel & Buskens, 2006). 
The impact of chronic diseases on individuals’ health status has been extensively studied 
(Lam, 1995). Nevertheless, there is no consensus on defining and classifying chronic 

































































diseases. These definitions exhibit heterogeneity in several characteristics, such as 
duration or latency, need for medical attention, effect on function, pathology, departure 
from well-being, contagiousness, associated risk factors, and responsiveness to treatment 
(Goodman et al., 2013). Therefore, there are different classifications of chronic diseases, 
which make comparisons across diseases difficult (Nordenfelt et al., 2014; Stewart, 
Greenfield & Hays, 1989; De-Bock et al., 1995; Smeele, et al., 1998; Krousel-Wood & 
Richard, 1994; Jaffe, Froom & Galambos, 1994; De Grauw et al., 1999).
Some studies aggregate chronic diseases to present results regardless of the impact of 
different diseases on individuals’ self-rated health or health status (Lam & Lauder, 2000; 
Lubetkin et al., 2005; Wu et al., 2015). For example, in 2012, the Centers for Medicare 
and Medicaid Services selected twenty-one condition indicators from the Chronic 
Condition Data Warehouse (CCW) (Centers for Medicare and Medicaid Services, 2012). 
These predefined conditions included a combination of common chronic conditions 
among older adults and were designed to allow for streamlined data extraction of disease 
cohorts from the CCW. However, when presenting the results of the study, 15 chronic 
diseases and multiple chronic conditions were presented in ranges of 0-1, 2-3, and 4-5 or 
more. Under this classification, a patient with asthma was considered equally important 
as a patient with cancer. In other studies, aggregation is done by incorporating a monetary 
value for the disease (Schneider, O’Donell & Dean, 2009; Ward & Schiller, 2013; Tinetti, 
Fried & Boyd, 2012). While this information is useful for financing the health care 
system, it is inaccurate for establishing health policies.
The impact of chronic diseases on health has been estimated in the literature using 
different methods. Two methods are particularly important: disability-adjusted life-years 
(DALYs) and HRQoL per patient. An estimation of losses using DALYs requires 
disability weights that quantify health losses for nonfatal consequences of diseases and 

































































injuries (WHO, 2008; Salomon et al., 2012). When the impact of a wide range of chronic 
conditions are expressed in terms of HRQoL, researchers calculate the impact that 
different diseases have on different measures of HRQoL per patient (Moussavi et al., 
2007; Saarni et al., 2006). In this study, we followed this second approach using a 
functional form that relates HRQoL measures to chronic diseases (Barton et al., 2008). 
Models similar to the one used in this article have been developed for the estimation of 
population norms with the goal of presenting variations in health indices because of 
changes in the values of the EQ-5D dimensions (Jansen et al., 2014; Greiner et al., 2003; 
Polsky et al., 2001). Other authors have used the same indices (e.g., SF-6D, VAS, EQ 
INDEX) and introduced dummy variables for clinical conditions as regressors (Barton et 
al., 2008).
Most studies take the perspective of the patient or of the health care system to calculate 
the impact of chronic diseases. This study conducts a broader calculation from a social 
perspective, presenting the result as a macro measure of the health of the population.
2. Objectives
The first objective of this study was to obtain a measure of the relative burden of chronic 
illness based on HRQoL using the EQ-5D-5L instrument. 
The second objective was to rank diseases by their association with the stock of health.
The third objective was to calculate the stock of health in Spain and the impact each 
chronic disease has on it.

































































3. Data and Methods
3.1 Survey design
The Spanish Health National Survey (ENSE) is jointly conducted by the Ministry of 
Health, Social Services and Equality and the National Institute of Statistics (MSSSI / INE) 
and conducted among a representative sample (by gender, age and region) of the 
noninstitutionalized population of Spain. Therefore, the results of this study are 
extrapolated to the Spanish population. Interviewers administered the survey in 
interviewees’ home using computers. The interview was conducted face to face among 
adults. A total of 26,502 interviews were conducted between July 2011 and June 2012. 
The working sample was restricted to adults aged 18 and over who responded to the ENSE 
(N = 20,587). All individuals assessed, by responding to a specific question, whether or 
not they were diagnosed with a chronic disease. There are no ethical issues to report; 
every respondent provided informed consent, and all data were anonymized.
3.2 HRQoL Variables
The EQ-5D is a self-administered questionnaire that consists of two parts: the descriptive 
system and the visual analog scale (VAS). 
The EQ-5D-5L descriptive system, a new version of the EQ-5D (Herdman et al., 2011), 
is the first part of the questionnaire, in which the current health status of individuals is 
described using 5 dimensions (mobility, self-care, usual activities, pain / discomfort, and 
anxiety / depression). The severity of each of these dimensions is rated on a five-point 
scale: no problem (1), slight problems (2), moderate problems (3), severe problems (4), 
extreme problems or inability (5). For each dimension each respondent indicated the level 
that best reflected his or her status at the moment of the interview. The overall health 

































































profile of every respondent was described by a five-digit number. Each digit took discrete 
values from 1 to 5, with 11111 considered the best possible health profile and 55555 the 
worst possible health profile. In total, 3125 possible health profiles can be found. 
Recently, the EuroQol group developed a study protocol to obtain measures of health 
states assessed by the EQ-5D-5L, which combines two measurement preferences 
techniques for health states, time trade off (TTO) and the discrete choice method (DC). 
This protocol was implemented in Spain among a representative sample (Ramos-Goñi et 
al., 2014). The EQ-5D-5L index measurements used in this paper were calculated using 
the results presented by Ramos-Goñi et al. (2017). The values of the EQ-5D-5L index 
were calculated to estimate quality-adjusted life years (QALYs) using [-1,1] range of 
values. 
In the visual analog scale (VAS), the respondent evaluated his or her current health status 
in a millimeter scale of 20 cm with the endpoints labeled "the best health you can 
imagine” (100) and "the worst health you can imagine" (0).
In this study, both the EQ-5D-5L index and the VAS were used as HRQoL measures. The 
VAS was self-reported by respondents and provided data on individuals’ subjective 
perceptions of all aspects of their health. The EQ-5D-5L index was elicited through 
preference measurement techniques and was restricted to the 5 dimensions of the EQ-5D.
3.3 Models specification.
We used a general linear model to estimate the association between quality of life 
measurements (i.e., the VAS and the EQ-5D-5L index) with each chronic disease and 
other sociodemographic variables. This model was also used to calculate the impact of 
combinations of diseases (i.e., a patient with more than one diagnosed chronic disease) 
on each of the two quality of life measures independently.

































































For the VAS, the models estimated were
VASi = α0 + CD_FREEi β0 + HBPi β1 + AMIi β2 + … + PIDCAi β30 + ui  (Model 
specification 1)
VASi = α0 + CD_FREEi β0 + HBPi β1 + AMIi β2 + … + PIDCAi β30 + WOMEN δ1 + 
age[25-34] δ2 +…+ age[>84] δ8  + INCOM_PS δ9  +…+ UNIVERSITY δ14 + ui     (Model 
specification 2)
for i = 20,587.
The same specification (Models 3 and 4) was done using the EQ-5D-5L index as the 
dependent variable instead of the VAS.
The complete list of regressors included the following variables: HBP (high blood 
pressure), AMI (acute myocardial infarction), OCD (other cardiovascular diseases), VV 
(varicose veins), OAR (osteoarthritis, arthritis or rheumatism), CBPu (chronic back pain 
upper), CBPl (chronic back pain lower), CA (chronic allergy), AS (asthma), COPD 
(chronic obstructive pulmonary disease), DIA (diabetes), SDU (stomach or duodenum 
ulcer), UI (urinary incontinence), HC (high cholesterol), CAT (cataract), CPS (chronic 
problems of the skin), CONS (constipation), CLD (cirrhosis, liver dysfunction), DEP 
(chronic depression) ANX (chronic anxiety), OMEN (other mental disorders), ESBH 
(embolism, stroke, cerebral hemorrhage), MFH (migraine or frequent headache), HEM 
(hemorrhoids), MT (malignant tumors), OST (osteoporosis), THYR (thyroid problems), 
PROS (prostate problems), MENO (menopausal problems), PIDCA (permanent injury or 
defect caused by accident), and the 30 chronic diseases diagnosed by a physician 
considered by the ENSE. Additional covariates included age (reference group: 18-24 
years old), gender (woman=1; otherwise=0), and level of education (reference group: 
illiterate, incomplete primary school, completed primary school, secondary education, 
medium level of education, and university or similar).

































































Note that in specification (1) and (3), the constant term (α0) is not interpretable. Rather, 
it is used to compute the differences in health outcomes between individuals with chronic 
disease and those who are free of disease (α0 + β0). For example, to calculate the 
difference in the VAS between individuals free of chronic disease and those with high 
blood pressure, we would use the following expression: (α0 + β0) - (α0 + β1). This would 
reduce to (β0 – β1). The change in one of the values of the dummy variables is interpreted 
as the decrease in health caused by the chronic disease. Thus, β1 (the coefficient for high 
blood pressure) represents a decrease from being diagnosed with the condition, 
controlling for the effect of the rest of variables included in the model. 
A weighted least squares model was used with population weights, ensuring estimates 
that are representative of the Spanish population. The weighting factor applied for the 
estimation of the regression models was provided by the National Spanish Institute of 
Statistics (INE). This factor appropriately weighted the sample by age group (five-year 
age groups from 0-4 to 60-64 and 65 and over), gender (men / women), geographical area 
(regions), and nationality (Spanish or foreigner)1. 
Gretl 1.9.7 and STATA SE 12.0 software are used to perform the data analysis. 
3.4 Output variables
Maximum stock of health: For a country, this was calculated as the maximum number of 
QALYs achievable by the population in one year, which is equivalent to having all 
individuals in full health in one year and therefore provided the best data on the 
hypothetical health status of a population.
1 The INE methodology document can be consulted at: 
https://www.mscbs.gob.es/en/estadEstudios/estadisticas/encuestaNacional/encuestaNac2011/Metodo
logiaENSE2011_12.pdf.

































































Stock of health free from chronic disease: This measures the stock of health for 
individuals in the population who have not been diagnosed with a chronic illness. In the 
model, (α0 + β0) represents the quantity of stock of health per capita when an individual 
does not have a chronic illness. The stock of health free of illness for a country is therefore 
(α0 + β0) times the number of individuals in the population.
Stock of health loss related to chronic disease: This measures the impact of each illness 
on the stock of health free of chronic illness. In the model, each parameter (from β1 to β30) 
represents the stock of health loss per capita when an individual has a specific illness. The 
stock of health loss related to a given chronic disease, such as high blood pressure, was 
calculated as β1 times the number of individuals with that specific illness. 
Actual stock of health in 2011: For each country, this was measured as the stock of health 
for the population free from chronic illness minus the sum of the stock of health losses 
associated with each chronic disease. For individuals free of chronic diseases, the sum of 
the stock of health loss is zero.
4. Results
The final working sample was the adult population older than 18 years of age. Table I 
shows the sociodemographic characteristics of the population by gender, age, level of 
education, diagnosed chronic condition, and number of conditions diagnosed. The mean 
age for men was 46.95 years, compared to 49.11 among women. For the population 
without chronic conditions, the mean age was 37.1 years, while individuals with any of 
the diagnoses listed were on average older than 45 years. Women had a higher average 
number of conditions than men. The mean number of conditions increased with age, while 

































































it decreased with education. The mean valuation of HRQoL was nearly 4 points higher 
for men (79.44 points in the VAS) than for women. 
Table I also shows how individuals diagnosed with illnesses like osteoporosis or prostatic 
problems have a higher mean number of conditions than individuals with other illnesses. 
The cumulative percentage of individuals diagnosed with three conditions or more was 
approximately 40%. The mean age for these individuals was 37 for the population with 
no chronic illnesses and 65 for those with 5 or 6 chronic illnesses. Additionally, mean 
VAS and mean EQ-5D-5L index values were higher for those with no chronic conditions 
(87.26 VAS, 0.979 EQ-5D-5L index) compared to those with 5 or 6 chronic conditions 
(63.67 VAS, 0.814 EQ-5D-5L index). 
Table I
Figure 1 shows the relationship that each disease had on HRQoL (e.g., VAS and EQ-5D-
5L index) in the entire sample, regardless of the number of chronic conditions with which 
respondents were diagnosed. The additional association of being diagnosed with multiple 
conditions makes it impossible to establish a relationship between the disease and the cost 
of that disease in terms of its health impact. In fact, comorbidities impacted more than 
50% of the sample. All diseases had values that were below the mean in comparison to 
those who did not have chronic illness. Figure 1 illustrates how other mental disorders 
and embolism, stroke, and cerebral hemorrhage are the conditions with the lowest mean 
values in the two HRQoL measures analyzed. 
Figure 1

































































It is interesting to ascertain the relationship of each disease on HRQoL, accounting for 
respondents having other chronic disease(s). This was achieved by estimating a 
multivariable linear regression model. The model obtained mean values associated with 
each of the chronic diseases and showed how they affected each of the HRQoL measures. 
The results are shown in Table II. 
The intercept plus the coefficient associated with CD_FREE in model specification (1) 
and (3) represents the mean value for the HRQoL measure (VAS or EQ-5D-5L index) for 
individuals who did not have any of the 30 chronic diseases listed in the survey (N = 
5564). The estimated values for each of the HRQoL measures were 87.26 and 0.979 for 
the VAS and EQ-5D-5L index, respectively, which was the same mean value shown in 
Table I. These values are the reference values used to calculate the mean values for each 
of the diseases in the Spanish population. For example, according to the model estimates, 
people suffering from a myocardial infarction have a mean value of 80.34 points in the 
VAS (80.34 = 87.26 - 6.92), while those diagnosed with high blood pressure in addition 
to a myocardial infarction would have a mean value of 77.13 (77.13 = 87.26 - 6.92 - 3.21). 
The model allows separation of the influence of each chronic disease as well as 
aggregation of health losses due to the combination of more than one chronic disease 
being diagnosed. The maximum number of chronic diseases for an individual was 20 (i.e., 
no respondents reported more than 20 out of the 30 listed). 
Using the model, we calculated and assigned an average impact value for each disease 
using HRQoL measures. However, for the mean value of the coefficients in the HRQoL 
measures for each disease, the model allowed calculations and assignments of the isolated 

































































impact of each chronic disease controlling for the effect of any other disease introduced 
as covariates in the model.
Table II
Figure 2 shows the ranking of chronic diseases by their impact on HRQoL (from worst 
to best). Note that “worst” and “best” are subjective terms since diagnostics were self-
reported by individuals. To obtain the ranking, we used model specifications (1) and (3). 
It seemed logical that not all chronic diseases had the same impact on respondents’ quality 
of life. Therefore, this arrangement was considered when analyses were performed on the 
number of chronic diseases declared. 
We observed that the first two diseases in the ranking were other mental disorders (1.87% 
of the population) and embolism, stroke, and cerebral hemorrhage (1.55%) and also had 
the strongest impact on HRQoL. Additionally, the total impact of the first twelve diseases 
in the ranking on the VAS showed a reduction for each disease of at least 8.5 points. Each 
of the last six diseases in the ranking had a maximum impact of 5 points on the VAS.
Figure 2
Table III shows the total association of each chronic disease on the stock of health for the 
overall population. Column (2), “Spanish population”, represents the expected number of 
individuals in the Spanish population with each of the chronic diseases listed in 2011. 

































































These values were obtained by multiplying the number of individuals in the sample 
reporting each disease (column (1), ENSE sample) by the ponderation to generate 
representative estimates for each of the disease groups in the Spanish population. Column 
(4), “Stock of health variation with respect to being free of disease”, represents the stock 
of health lost in the population because of each disease. The variation in the stock of 
health was calculated for each chronic disease by multiplying the coefficient estimates of 
the regression by the number of individuals with that disease (column (3)). As a result, 
the numbers in column (4) represent how much stock of health the Spanish population 
lost due to each chronic disease. Finally, Column (5) shows the percentage of variation 
in the stock of health with respect to the stock of health in the population free of chronic 
diseases. This was calculated using the information in column (4), with 100% assigned 
to the population free of chronic diseases.
The maximum stock of health for any population would be equal to the total number of 
individuals in that population (Spain in the 2011-2012 year (P) = 40,852,036). To 
determine this number, it is necessary to assume that the maximum value for a state of 
perfect health for an individual in a year is 1. 
Table III and Figure 2 show that diseases like cardiovascular diseases and other 
embolism, stroke, and cerebral hemorrhage have a very high impact (at the patient level) 
on HRQoL but a much lower impact on HRQoL at the population level due to the lower 
prevalence of these diagnoses. High blood pressure has a larger population-level impact 
since one out of four individuals were diagnosed with it. At the bottom of the ranking, we 
observed that the ranking of illnesses was similar for both HRQoL measures. The low 
position of conditions such as menopausal and prostate problems were not surprising 
given their low incidence and the specificity of these diseases. Similar results were also 

































































found for cirrhosis and liver dysfunction, which was low in ranking when we considered 
the impact at the population level. 
Table III
Given that the Spanish National Health Service already underestimates the relationship 
of chronic diseases on HRQoL, the loss in the stock of health in a year due to a specific 
illness is underestimated by the regression model. Figure 3 illustrates how the estimated 
VAS and EQ-5D-5L index values are lower than the population VAS and EQ-5D-5L 
index mean values. Individuals who report having no chronic illness have the same 
estimated values and observed values and therefore have a difference of zero. The 
opposite is shown for individuals with one or more chronic illnesses. The figure below 
shows the difference between population estimated values and sample mean values for 
the EQ-5D-5L index and VAS for each chronic disease. The estimated value is the impact 
on the stock of health controlling for the effect of other chronic diseases. The actual value 
is the mean among individuals who have only that specific disease. The difference 
between the actual and estimated values represent the consequence of comorbidities. 
Some significant differences between illnesses can be observed. For example, urinary 
incontinence (UI) has the highest difference, and chronic allergy (CA) has the lowest. 
The difference between estimated and mean values for those two are the highest (a 
difference of 16 points in the VAS and 0.14 in the EQ-5D-5L index).
Figure 3

































































In aggregate terms, chronic diseases represent 8.98 million units in the VAS of the stock 
of health losses for a country compared to a country free of those diseases. In Spain, the 
actual stock of health was 31.86 million units in the VAS for 2011. This implies a 
decrease of 32% in maximum attainable health and of almost 19% in the number obtained 
for a society free from chronic diseases. 
Output variables: Health stock in VAS units (Spain, year 2011)
Maximum stock of health: 46,819,160 (100%)
Stock of health free from chronic disease: 40,852,036 (87.26%)
Stock of health loss of chronic disease (for all): 8,985,435 (19.19%)
Actual stock of health in 2011: 31,866,602 (68.07%)
5. Discussion
We analyzed data from the ENSE 2011-2012 survey to establish a ranking of chronic 
diseases in terms of HRQoL in the Spanish population. In this survey, three questions 
regarding chronic diseases appeared, and we analyzed responses to the question assessing 
whether participants were diagnosed with a chronic disease. This question was the most 
restrictive and was also the most reliable, particularly in comparison to the other two 
questions which asked respondents to report whether they ever experienced a chronic 
disease or whether they experienced one in the past 12 months. 

































































The ranking we developed improves current evaluation methods for the impact of chronic 
diseases because it establishes an ordering of chronic illnesses by their impact on HRQoL. 
In doing so, we avoided summing the impact of each chronic illness, which incorrectly 
assumes they all have the same weight. Suffering from more diseases does not necessarily 
imply having a worse health status. Rather, health status depends on the weight the 
diseases have on the stock of health.
Both HRQoL measures, VAS and EQ-5D-5L index, yielded similar results in terms of 
the health impacts and ranking of diseases. There is a difference, however, on what each 
if these tools reflect. This difference is that VAS measures but does not assess 
preferences-based information. The EQ-5D-5L index, derived from the combination of 
the health profile description and a social tariff, assesses preference-based information. 
For broader objectives such as measuring or describing the health of a population, 
considering the VAS is still recommended as a relevant source of information.
Examining health losses for a society by allocating a weight to each of the chronic 
diseases actually measures the individuals’ willingness to pay in points of HRQoL to not 
suffer from that specific illness. 
There are other HRQoL measures that are extracted from the EQ-5D-5L, including the 
sum score (Hinz et al., 2014). The sum score is obtained by adding the corresponding 
levels of the 5 dimensions for each health profile. In this study, the EQ-5D-5L index was 
used instead of the sum score because prior studies have found that it yields results that 
are almost exactly the same, and perhaps more accurate (Hinz et al., 2014). Additionally, 
country-specific weights for the EQ-5D-5L have already been developed for Spain 
(Ramos-Goñi et al., 2017).  

































































In this paper, we considered cost in terms of health to be of greater interest than the 
monetary cost of illnesses. Prices may vary depending on innovation or increases in 
productivity. However, variations in terms of the stock of health are maintained. While 
estimates of the prices are highly useful at the patient level because they approximate the 
costs faced by individuals due to their illness, considering that value in terms of 
population health can help set innovative research policies and better assist with illness 
prevention and intervention efforts.
In table II we estimated an additional model with gender, age groups, and education as 
controls. However, to obtain the stock of health of the population, we will still be using 
the model only with dummies for chronic diseases as regressors. Introducing controls 
would change the interpretation of the coefficients. For example, if we include age[>81] 
in the model, and we take the coefficient for High Blood Pressure (HBP), this will give 
the following interpretation of the coefficient: “the impact on the stock of health of having 
HBP, controlling for the impact on the stock of health of any other chronic disease, but 
also controlling for the impact on the stock of health of being over 81 years old”. In this 
paper, though, we present the effect on the stock of health due to each of the chronic 
diseases, after having controlled for all other chronic diseases.
The consequence of comorbidity was assessed using a multiple regression model. The 
model provided estimates of stock of health losses due to any possible illness and 
combination of illnesses for individuals reporting more than one disease. Therefore, it 
allowed for comparisons of the difference between the stock of health losses related to 
having each of the combinations of illnesses. However, we did not examine the ranking 
of comorbidities, which would show the most frequent combination of diseases observed 
among the population analyzed. Rather, we were mainly interested in providing a ranking 

































































of diseases by their importance. Further research could focus on analyzing diseases by 
their incidence in the sample.
There are some limitations in this study. First, the ENSE survey was not specifically 
designed for this study. The principal aim of the ENSE was to collect information about 
the health status of the Spanish population, health determinants, and health utilization and 
access to services. Second, the list of chronic diseases in the survey came from a closed 
list determined by the Spanish Ministry of Health. All conditions had the common 
characteristic of having a duration of more than 6 months and therefore could be 
considered chronic illnesses. However, the survey did not provide a full list of chronic 
diseases. 
Further research should focus on collecting similar information in other countries to allow 
for cross-cultural comparisons.
6. Conclusion 
Chronic diseases in Spain represent 19.19% of the stock of health losses compared to a 
country free of those diseases. In Spain, the stock of health in 2011 was 31.86 million 
units in the VAS, which is less than 46.81 million (the maximum attainable for the 
country) and 40.85 million (the amount needed for the country to be free from chronic 
diseases).
At the individual level, the diseases that have a stronger impact on loss of stock of health 
in Spain were mental illness and embolism, stroke, or cerebral hemorrhage. At the 
population level, the conditions with the largest impact were osteoarthritis, arthritis, or 
rheumatism, chronic back pain, and high blood pressure.
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Table I. Sociodemographic and clinical characteristics and HRQoL mean values for the 
ENSE population






















Gender TOTAL Men Woman
Men 10013 48.64 46.95 1.83 79.44 0,938 79.44 0,938
Women 10574 51.36 49.11 2.80 75.73 0,892 75.73 0,892
Age
[18-24] 1820 8.84 21.01 0.62 88.16 0,976 89.33 0,980 86.99 0,972
[25-34] 3740 18.17 29.85 0.88 85.37 0,970 86.21 0,974 84.49 0,966
[35-44] 4244 20.62 39.50 1.37 81.41 0,950 82.10 0,957 80.68 0,942
[45-54] 3663 17.79 49.36 2.18 77.17 0,928 78.24 0,943 76.12 0,913
[55-64] 2812 13.66 59.33 3.32 73.16 0,899 74.97 0,926 71.46 0,873
[65-74] 2162 10.5 69.19 4.23 69.82 0,865 72.67 0,910 67.29 0,826
[75-84] 1609 7.82 79.06 5.16 62.57 0,781 65.39 0,831 60.63 0,747
[85+] 535 2.6 88.63 5.33 54.55 0,625 58.29 0,698 52.55 0,586
Level of Education
Illiterate 406 1.97 69.60 5.09 58.39 0,712 64.20 0,804 55.59 0,667
Incomplete Primary School 2025 9.84 68.43 4.41 64.92 0,803 69.09 0,861 61.80 0,760
Complete Primary School 2242 10.89 57.98 3.48 70.89 0,872 74.20 0,909 67.83 0,838
Secondary Education 6620 32.16 46.30 2.27 78.02 0,920 79.93 0,941 76.03 0,898
Medium Level of Education 5932 28.81 40.93 1.57 81.81 0,950 82.65 0,959 80.96 0,941
University or Similar 3359 16.32 42.62 1.41 82.81 0,961 82.49 0,964 83.10 0,958
Acronym Illness
CD_FREE Free of Illness 5564 27.03 37.16 0 87.26 0,980 87.57 0,981 86.87 0,978
HBP High Blood Pressure 5388 26.17 63.47 4.98 66.89 0,832 81.33 0,968 81.27 0,968
AMI Acute Myocardial Infarction 472 2.29 68.65 6.45 57.36 0,770 78.08 0,946 53.53 0,979
OCD Other Cardiovascular Diseases 1541 7.49 67.26 6.54 59.32 0,754 79.22 0,951 73.81 0,936
VV Varicose Veins 2994 14.54 60.06 5.68 67.09 0,819 80.68 0,979 84.29 0,967
OAR Osteoarthritis, Arthritis or Rheumatism 5019 24.38 66.08 6.04 61.53 0,770 74.98 0,925 74.18 0,898
CBPu Chronic Back Pain, Upper 3867 18.78 56.45 5.91 65.04 0,798 78.80 0,955 78.95 0,937
CBPl Chronic Back Pain, Lower 4558 22.14 56.28 5.51 65.60 0,809 78.99 0,937 78.12 0,919
CA Chronic Allergy 2526 12.27 45.71 4.15 74.56 0,898 83.31 0,974 82.91 0,964
AS Asthma 1101 5.35 47.07 4.95 70.96 0,868 84.08 0,976 83.85 0,972
COPD Chronic Obstructive Pulmonary Disease 1115 5.42 62.07 6.64 60.92 0,781 72.84 0,930 73.27 0,936
DIA Diabetes 1857 9.02 65.55 5.86 62.02 0,789 77.18 0,958 72.36 0,904
SDU Stomach or Duodenum Ulcer 1020 4.95 59.35 5.94 64.45 0,825 75.71 0,957 77.56 0,922
UI Urinary Incontinence 962 4.67 72.51 8.04 53.57 0,643 75.88 0,876 76.01 0,816
HC High Cholesterol 4543 22.07 59.71 4.99 68.63 0,852 77.44 0,951 75.61 0,918
CAT Cataract 2326 11.30 73.39 6.37 61.79 0,762 75.11 0,917 69.35 0,830
CPS Chronic Problems of the Skin 1045 5.08 52.49 5.67 67.03 0,825 76.30 0,946 78.42 0,940
CONS Constipation 1030 5.00 61.32 7.43 59.91 0,730 72.00 0,913 70.03 0,866
CLD Cirrhosis, Liver Dysfunction 241 1.17 58.46 6.33 60.23 0,770 70.62 0,936 63.01 0,853
DEP Chronic Depression 1921 9.33 58.43 7.12 57.22 0,695 65.04 0,769 65.59 0,805
ANX Chronic Anxiety 1826 8.87 54.26 6.66 59.36 0,723 67.19 0,857 65.61 0,795
OMEN Other Mental Disorders 385 1.87 63.30 5.77 50.08 0,595 64.02 0,774 49.03 0,583
ESBH Embolism, Stroke, Cerebral Hemorrhage 321 1.56 69.02 6.94 51.38 0,635 63.70 0,781 50.03 0,596
MFH Migraine or Frequent Headache 2132 10.36 49.81 5.39 66.98 0,827 74.63 0,914 72.60 0,877
HEM Hemorrhoids 1483 7.20 58.45 6.39 65.17 0,815 74.04 0,911 67.98 0,842
MT Malignant Tumors 738 3.58 64.45 5.92 60.88 0,790 63.07 0,832 63.29 0,803
OSTH Osteoporosis 1159 5.63 68.75 7.56 58.80 0,718 59.64 0,733 60.18 0,742
THYR Thyroid Problems 1234 5.99 54.96 5.21 69.84 0,844 74.31 0,924 71.27 0,854
PROS Prostate Problems 832 4.04 72.74 5.73 64.87 0,828 65.55 0,837 .  .
MENO Menopausal Problems 646 3.14 55.49 6.28 65.44 0,809 .  . 66.62 0,819
PIDCA Permanent Injury or Defect by Accident 1224 5.95 51.14 4.88 68.63 0,825 70.91 0,860 65.31 0,768
Number of Illnesses (Dx)
0 5564 27.03 37.16 0 87.26 0,980 87.57 0,981 86.87 0,978
1-2 6837 33.21 46.29 1.39 80.46 0,951 80.48 0,955 80.45 0,947
3-4 3697 17.96 55.66 3.43 72.40 0,902 72.69 0,918 72.17 0,889
5-6 2123 10.31 61.96 5.43 63.67 0,814 62.86 0,838 64.17 0,800
7-8 1230 5.97 65.45 7.42 56.88 0,726 56.94 0,744 56.87 0,719
9-10 616 2.99 68.00 9.40 52.75 0,654 51.05 0,684 53.41 0,642
11-15 471 2.29 69.58 12.36 46.02 0,536 42.75 0,564 46.90 0,528
16-20 49 0.25 69.00 16.84 35.77 0,387 45.56 0,354 33.49 0,395
Total 20587 100 48.06 2.32 77.53 0,914 79.44 0,938 75.73 0,892
Note: Weighting factor applied (includes gender, age and geographical area) to ensure sample representativeness of 
the Spanish population.

































































Table II. Model results (WLS) for VAS and EQ-5D-5L index
VAS EQ INDEX
(1) (2) (3) (4)
Variables Coef. Std. Err. Coef. Std. Err. Coef. Std. Err. Coef. Std. Err.
intercept 83.307 0.220 ** 81.432 0.923 ** 0.9867 0.0017 ** 0.9227 0.0068 **
CD_FREE 3.954 0.286 ** 2.583 0.289 ** −0.0067 0.0022 ** -0.0133 0.0022 **
HBP -3.216 0.291** -1.996 0.294 ** −0.0239 0.0022 ** -0.0163 0.0022 **
AMI -6.925 0.766 ** -6.150 0.755 ** −0.0274 0.0059 ** -0.0195 0.0058 **
OCD -5.349 0.474 ** -4.408 0.469 ** −0.0470 0.0037 ** -0.0354 0.0036 **
VV -0.401 0.352 0.210 0.349 −0.0072 0.0027 ** -0.0040 0.0027
OAR -7.521 0.331 ** -5.528 0.340 ** −0.0721 0.0026 ** -0.0557 0.0026 **
CBPu -1.859 0.348 ** -2.068 0.342 ** −0.0265 0.0027 ** -0.0283 0.0026 **
CBPl -3.475 0.324 ** -3.509 0.319 ** −0.0328 0.0025 ** -0.0352 0.0024 **
CA 0.987 0.345 ** -0.198 0.342 0.0074 0.0027 ** 0.0002 0.0026
AS -0.844 0.510 * -1.356 0.503 ** −0.0041 0.0040 -0.0039 0.0039
COPD -4.728 0.530 ** -4.053 0.522 ** −0.0280 0.0041 ** -0.0226 0.0040 **
DIA -5.187 0.427 ** -4.433 0.422 ** −0.0386 0.0033 ** -0.0350 0.0032 **
SDU -2.318 0.531 ** -2.337 0.523 ** 0.0063 0.0041 0.0022 0.0040
UI -5.187 0.619 ** -3.276 0.618 ** −0.1040 0.0048 ** -0.0738 0.0047 **
HC -0.711 0.295 ** -0.487 0.292 * 0.0057 0.0023 * 0.0018 0.0022
CAT -2.550 0.419 ** 0.042 0.436 −0.0378 0.0032 ** -0.0057 0.0033 *
CPS -1.795 0.502 ** -2.503 0.494 ** −0.0154 0.0039 ** -0.0203 0.0038 **
CONS -2.352 0.561 ** -1.961 0.552 ** −0.0428 0.0044 ** -0.0354 0.0042 **
CLD -5.954 1.046 ** -5.704 1.028 ** −0.0427 0.0080 ** -0.0444 0.0078 **
DEP -5.761 0.505 ** -5.506 0.498 ** −0.0839 0.0039 ** -0.0854 0.0038 **
ANX -5.260 0.489 ** -5.679 0.482 ** −0.0676 0.0038 ** -0.0724 0.0037 **
OMEN -15.615 0.872 ** -13.536 0.863 ** −0.1972 0.0065 ** -0.1687 0.0064 **
ESBH -11.047 0.958 ** -10.118 0.942 ** −0.1457 0.0074 ** -0.1343 0.0072 **
MFH -2.482 0.373 ** -3.017 0.370 ** −0.0140 0.0029 ** -0.0168 0.0028 **
HEM -0.681 0.462 -0.862 0.455 * 0.0098 0.0036 ** 0.0038 0.0035
MT -7.186 0.635 ** -6.731 0.625 ** −0.0435 0.0049 ** -0.0400 0.0047 **
OSTH -2.494 0.560 ** -1.681 0.554 ** −0.0435 0.0043 ** -0.0378 0.0042 **
THYR 0.130 0.474 0.033 0.471 −0.0051 0.0037 -0.0084 0.0036 **
PROS -0.658 0.611 0.394 0.622 0.0155 0.0047 ** 0.0213 0.0047 **
MENO -1.754 0.656 ** -1.525 0.654 ** −0.0116 0.0051 * -0.0168 0.0050 **
PIDCA -2.458 0.465 ** -2.937 0.459 ** −0.0415 0.0036 ** -0.0464 0.0035 **
WOMAN -0.469 0.228 ** -0.0073 0.0017 **
Age [25-34] -2.079 0.423 ** -0.0008 0.0032
Age [35-44] -4.289 0.419 ** -0.0088 0.0032 **
Age [45-54] -5.695 0.439 ** -0.0083 0.0034 **
Age [55-64] -5.560 0.481 ** -0.0040 0.0037
Age [65-74] -5.613 0.539 ** -0.0086 0.0041 **
Age [75-84] -8.867 0.620 ** -0.0532 0.0047 **
Age [>84] -14.980 0.845 ** -0.1801 0.0064 **
Incom_PS 3.389 0.848 ** 0.0598 0.0062 **
Complete_PS 4.485 0.849 ** 0.0766 0.0062 **
Secondary 6.399 0.826 ** 0.0763 0.0060 **
Medium 7.142 0.837 ** 0.0806 0.0061 **
University 7.902 0.854 ** 0.0871 0.0063 **
N obs 20421 20421 20587 20587
F-Statistic 369.02 ** 287.01 ** 552.49 ** 449.20 **
R-squared 0.3594 0.3826 0.4545 0.490
Adj R-squar. 0.3584 0.3813 0.4537 0.489

































































Where CD_FREE (chronic disease free), HBP (high blood pressure), AMI (acute myocardial infarction), OCD (other 
cardiovascular diseases), VV (varicose veins), OAR (osteoarthritis, arthritis or rheumatism), CBPu (chronic back 
pain, upper), CBPl (chronic back pain lower), CA (chronic allergy), AS (asthma), COPD (chronic obstructive 
pulmonary disease), DIA (diabetes), SDU (stomach or duodenum ulcer), UI (urinary incontinence), HC (high 
cholesterol), CAT (cataract), CPS (chronic problems of the skin), CONS (constipation), CLD (cirrhosis, liver 
dysfunction), DEP (chronic depression) ANX (chronic anxiety), OMEN (other mental disorders), ESBH (embolism, 
stroke, cerebral hemorrhage), MFH (migraine or frequent headache), HEM (hemorrhoids), MT (malignant tumors), 
OST (osteoporosis), THYR (thyroid problems), PROS (prostate problems), MENO (menopausal problems), PIDCA 
(permanent injury or defect caused by accident). Additional covariables are Age (reference group [18-24]), WOMAN 
(woman =1, 0 otherwise) Level of education. (reference group (Illiterate); Incomplete_PS: incomplete primary 
school; Complete_PS: complete primary school; Secondary: secondary education; Medium: medium level of 
education; University: university or similar).
* p < 0.10, ** p < 0.05





















































































(1) (2) = P*((1)/N) (3) (4) = ((3)/100)*(2) (5)=(4)/HSF %




OAR 5019 11413469 -11.475 -1309696 -3.21%
High Blood Pressure HBP 5388 12252594 -7.170 -878511 -2.15%
Chronic Back Pain 
Lower CBPl 4558 10365131 -7.429 -770026 -1.88%
Chronic Back Pain 
Upper CBPu 3867 8793760 -5.813 -511181 -1.25%
High Cholesterol HC 4543 10331020 -4.665 -481942 -1.18%
Chronic Depression DEP 1921 4368455 -9.715 -424395 -1.04%
Diabetes DIA 1857 4222915 -9.141 -386017 -0.94%
Chronic Anxiety ANX 1826 4152420 -9.214 -382604 -0.94%
Cataract CAT 2326 5289446 -6.504 -344026 -0.84%
Other Cardiovascular 
Diseases OCD 1541 3504315 -9.303 -326006 -0.80%
Migraine or Frequent 
Headache MFH 2132 4848280 -6.436 -312035 -0.76%
Varicose Veins VV 2994 6808513 -4.355 -296511 -0.73%
Chronic Bronchitis, 
Emphysema, COPD COPD 1115 2535568 -8.682 -220138 -0.54%
Urinary Incontinence UI 962 2187638 -9.141 -199972 -0.49%
Malignant Tumors MT 738 1678251 -11.140 -186957 -0.46%
Permanent Injury or 
Defect Caused by 
Accident
PIDCA 1224 2783440 -6.412 -178474 -0.44%
Other Mental 
Disorders OMEN 385 875510 -19.569 -171329 -0.42%
Chronic Allergy CA 2526 5744256 -2.967 -170432 -0.42%
Osteoporosis OSTH 1159 2635627 -6.448 -169945 -0.42%
Hemorrhoids HEM 1483 3372420 -4.635 -156312 -0.38%
Constipation CONS 1030 2342274 -6.306 -147704 -0.36%
Stomach or 
Duodenum Ulcer SDU 1020 2319533 -6.272 -145481 -0.36%
Chronic Problems 
of the Skin CPS 1045 2376385 -5.749 -136618 -0.33%
Asthma AS 1101 2503732 -4.798 -120129 -0.29%
Acute Myocardial 
Infarction AMI 472 1073353 -10.879 -116770 -0.29%
Embolism, Stroke, 
Cerebral Hemorrhage ESBH 321 729971 -15.001 -109503 -0.27%
Thyroid Problems THYR 1234 2806181 -3.824 -107308 -0.26%
Prostate Problems PROS 832 1892012 -4.612 -87260 -0.21%
Menopausal Problems MENO 646 1469038 -5.708 -83853 -0.21%
Cirrhosis, Liver 
Dysfunction CLD 241 548047 -9.908 -54300 -0.13%

































































Figure 1. Impact of chronic disease on VAS and EQ-5D-5L index
The boxes represent values between the 25th percentile (bottom) and 75th percentile (top). 
The horizontal line inside the boxes represents the median value in the sample. Values 
outside of the 95% confidence intervals are not included.

































































Figure 2. Ranking of chronic diseases by their impact on HRQoL measures 
(VAS and EQ-5D-5L index)
































































Where HBP (high blood pressure), AMI (acute myocardial infarction), OCD (other cardiovascular diseases), VV 
(varicose veins), OAR (osteoarthritis, arthritis or rheumatism), CBPu (chronic back pain, upper), CBPl (chronic back 
pain, lower), CA (chronic allergy), AS (asthma), COPD (chronic obstructive pulmonary disease), DIA (diabetes), SDU 
(stomach or duodenum ulcer), UI (urinary incontinence), HC (high cholesterol), CAT (cataract), CPS (chronic problems 
of the skin), CONS (constipation), CLD (cirrhosis, liver dysfunction), DEP (chronic depression) ANX (chronic 
anxiety), OMEN (other mental disorders), ESBH (embolism, stroke, cerebral hemorrhage), MFH (migraine or frequent 
headache), HEM (hemorrhoids), MT (malignant tumors), OST (osteoporosis), THYR (thyroid problems), PROS 
(prostate problems), MENO (menopausal problems), PIDCA (permanent injury or defect caused by accident).

































































Figure 3. Differences between the mean of observed values and estimated VAS and EQ-5D-




































































Estimated VAS - Mean VAS Estimated EQ INDEX - Mean EQ INDEX
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